The Vein That Learns to Belong: VERIGRAFT’s Biological Bet on Curing Chronic Venous Insufficiency
Petter Björquist CEO, VERIGRAFT Chronic venous insufficiency affects an estimated 150 million people worldwide, yet the clinical toolkit has...
Petter Björquist CEO, VERIGRAFT Chronic venous insufficiency affects an estimated 150 million people worldwide, yet the clinical toolkit has...
A Vanguard Publications Q&A with Ayaan, Convexia Bio.
Veeva Systems — the enterprise software giant that has long dominated clinical, regulatory, and commercial operations for life sciences...
A plant-derived compound with a novel mechanism, eight weeks of effect from three days of dosing, and a Phase...
At an industry conference, we spoke with Yann Péoc’h, World Operations Transformation Excellence Director at Servier, about how deep...
At the 2025 Veeva Commercial Summit, we spoke with Eric Toron, Executive Director and Head of Operations at MSD...
At Veeva Commercial Summit Europe, we spoke with Andreas Gerloff, Director of Medical Excellence Operations at Daiichi Sankyo Europe,...
At the 2025 Veeva Commercial Summit Europe, we spoke with Michelle Bridenbaker, Corporate Medical Information Lead at Recordati and...
As the pharmaceutical industry faces an unprecedented surge of product launches, most companies plan to handle this expansion without...
In this interview, Christoph Bug, VP Global Medical Veeva, explains how Medical Affairs must evolve from tracking tasks to...